Acta Cryst. (1997). C53, 608-610

## 2,6-Diazido-9-(carboxymethyl)purine Methyl Ester

GEETA SOOD, CARL H. SCHWALBE AND WILLIAM FRASER

Pharmaceutical Sciences Institute, Aston University, Aston Triangle, Birmingham B4 7ET, England. E-mail: c.h. schwalbe@aston.ac.uk

(Received 21 October 1996; accepted 23 December 1996)

## Abstract

The title compound (methyl 2,6-diazidopurine-9-acetate,  $C_8H_6N_{10}O_2$ ) is a potential intermediate for the synthesis of peptidic nucleic acids containing diaminopurine. Its two azido groups are approximately parallel and at their attachment points, the internal ring angles are 1.4 (3)° smaller than in the dichloro homologue.

## Comment

The use of peptidic nucleic acids (PNA's; Hyrup & Nielsen, 1996) containing the DNA bases (Dueholm et al., 1994), in addition to pseudoisocytosine (Egholm et al., 1995), offers the possibility of inhibiting gene expression in a controlled manner through triplex formation (Thuong & Hélène, 1993) with target nucleic acid sequences. Our interest in the development of PNA's containing other purine bases, including 2,6diaminopurine, has prompted the synthesis of 2.6-diazido-9-(carboxymethyl)purine methyl ester, (1), as an intermediate for the synthesis of PNA's. Alkylation of 2,6-dichloropurine (Chan, Sood, Schwalbe & Fraser, 1995) using methyl bromoacetate gave 2,6-dichloro-9-(carboxymethyl)purine methyl ester, (2), which, on treatment with sodium azide at elevated temperature, resulted in substitution of both of the chloro groups giving the title compound, (1).



Many geometrical features of (1) (Table 1) resemble those previously found in the ethyl ester homologue of (2) (Chan, Sood, Schwalbe & Fraser, 1995). The atoms of the heterocycle are coplanar within  $\pm 0.013$  (2) Å and the side chain avoids steric interference with

© 1997 International Union of Crystallography Printed in Great Britain – all rights reserved the heterocycle by means of a large twist about the N9—C10 bond. The 2,6-diazido-substituted compound (1), however, exhibits increased external N1—C2—N21 and N1—C6—N61 angles [by 3.1 (4) and 3.9 (4)°, respectively] and decreased internal N1—C2—N3 and N1—C6—C5 angles [both by 1.4 (4)°] compared with the ethyl ester homologue of (2). Although most bond distances are similar to within  $3\sigma$ , C5—C6 is longer in (1) by 0.025 (6) Å and N9—C10 shorter by 0.017 (5) Å.

Torsion angles near  $0^{\circ}$  for both N1—C2—N21—N22 and N1—C6—N61—N62 indicate that the two azido groups are almost parallel, resembling a pair of jaws. A similar disposition of azido groups was found in the crystal structure of 2,4-diazido-6-diazoacetylpyrimidine (Kartsev, Aliev, Voronina & Atovmyan, 1990), while one of the azido groups is rotated by *ca* 180° about the C—N bond in 2,4-diazido-5-iodopyrimidine (Allen, Buckland & Nowell, 1976).



Fig. 1. ORTEPII view (Johnson, 1976) of the title molecule. Displacement ellipsoids are shown at the 50% probability level. H atoms are shown as small spheres with arbitrary radii.

### Experimental

Preparation of 2,6-dichloro-9-(carboxymethyl)purine methyl ester, (2): to a solution of 2,6-dichloropurine (1.00 g, 5.31 mmol) in dry MeCN (20 ml) was added K<sub>2</sub>CO<sub>3</sub> (0.88 g, 6.38 mmol) and methyl bromoacetate (1.00 g, 6.38 mmol). After stirring at room temperature for 48 h under argon, the product solution was filtered and the solvent evaporated under vacuum. The residue was subjected to flash column chromatography on silica and the product eluted with EtOAc. Recrystallization from MeOH gave the title compound (2) (538 mg, 39%; m.p. 424-426 K) as colourless crystals. TLC (EtOAc):  $R_f$  0.25. IR (KBr disc):  $\nu_{max}$  3108, 2998, 2958, 1739, 1596, 1556, 1379, 1340, 1234, 1157, 951, 879 cm<sup>-1</sup>. <sup>1</sup>H NMR [250.1 MHz; (CD<sub>3</sub>)<sub>2</sub>SO]:  $\delta$  3.73 (s, 3H, CH<sub>3</sub>), 5.26 (s, 2H, CH<sub>2</sub>), 8.70 (s, 1H, H-8). <sup>13</sup>C NMR [62.1 MHz; (CD<sub>3</sub>)<sub>2</sub>SO]: δ 45.9 (CH<sub>2</sub>), 54.0 (CH<sub>3</sub>), 130.3 (C-5), 150.1 (C-8), 150.3 (C-2), 151.5 (C-4 and C-6), 162.2 (CO). MS (EI): m/z (Ir) 264  $(M^+, 6\%), 262 (M^+, 30\%), 260 (M^+, 45\%), 204 (13\%), 203$ (23%), 201 (33%), 77 (40%), 59 (100%). Analysis calculated for C<sub>8</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>: C 36.8, H 2.3, Cl 27.1, N 21.4%; found: C 36.8, H 2.3, Cl 27.2, N 21.1%.

Preparation of 2,6-diazido-9-(carboxymethyl)purine methyl ester, (1): a mixture of (2) (351 mg, 1.34 mmol), sodium azide (95 mg, 6.15 mmol), Me<sub>2</sub>CO (15 ml) and MeOH (55 ml) was refluxed for 96 h at 353 K. The solvent was evaporated and the residue then subjected to flash chromatography, eluting with EtOAc. Recrystallization from MeOH gave the title compound (1) (74 mg, 20%; m.p. 399-401 K) as pale yellowbrown crystals. TLC (EtOAc):  $R_f$  0.34. IR (KBr disc):  $\nu_{max}$ 3109, 2949, 2131, 1737, 1616, 1577, 1348, 1234, 995, 788, 626 cm<sup>-1</sup>. <sup>1</sup>H NMR [250.1 MHz; (CD<sub>3</sub>)<sub>2</sub>SO]:  $\delta$  3.71 (s, 3H, CH<sub>3</sub>), 5.16 (s, 2H, CH<sub>2</sub>), 8.41 (s, 1H, H-8). <sup>13</sup>C NMR [62.1 MHz; (CD<sub>3</sub>)<sub>2</sub>SO]:  $\delta$  40.7 (CH<sub>2</sub>), 52.9 (CH<sub>3</sub>), 120.8 (C-5), 146.2 (C-8), 152.9, 154.3, 155.1 (C-2, C-4 and C-6), 168.2 (CO). MS (electrospray): m/z (I<sub>r</sub>): 274 (M + H 28%), 246 (18%), 160 (44%), 107 (28%), 95 (46%), 80 (74%), 59 (100%). Accurate mass for  $C_8H_6N_{10}O_2$ : calculated 274.068; found 274.068.

Cu  $K\alpha$  radiation

Cell parameters from 25

 $0.50 \times 0.15 \times 0.05$  mm

Pale yellow-brown

 $\lambda = 1.54178 \text{ Å}$ 

reflections  $\theta = 22.2 - 44.3^{\circ}$ 

 $\mu = 1.015 \text{ mm}^{-1}$ 

T = 293(2) K

 $R_{\rm int} = 0.0580$ 

 $\theta_{\rm max} = 67.7^{\circ}$ 

 $k = 0 \rightarrow 14$ 

 $l = -9 \rightarrow 9$ 

 $h = -15 \rightarrow 15$ 

3 standard reflections

frequency: 120 min

intensity decay: 19%

Lath

#### Crystal data

 $C_8H_6N_{10}O_2$   $M_r = 274.23$ Monoclinic  $P2_1/c$  a = 12.761 (2) Å b = 12.1276 (13) Å c = 7.9969 (9) Å  $\beta = 102.907 (10)^\circ$   $V = 1206.3 (3) Å^3$  Z = 4  $D_x = 1.510 \text{ Mg m}^{-3}$  $D_m \text{ not measured}$ 

#### Data collection

Enraf-Nonius CAD-4 diffractometer  $\omega/2\theta$  scans Absorption correction: none 4316 measured reflections 2173 independent reflections 1384 reflections with  $I > 2\sigma(I)$ 

#### Refinement

Refinement on  $F^2$  $(\Delta/\sigma)_{\rm max} = 0.004$  $\Delta \rho_{\text{max}} = 0.27 \text{ e } \text{\AA}^{-3}$  $\Delta \rho_{\text{min}} = -0.24 \text{ e } \text{\AA}^{-3}$ R(F) = 0.0629 $wR(F^2) = 0.1961$ S = 1.036Extinction correction: none 2172 reflections Scattering factors from 205 parameters International Tables for All H atoms refined Crystallography (Vol. C)  $w = 1/[\sigma^2(F_o^2) + (0.0999P)^2]$ + 0.0504Pwhere  $P = (F_o^2 + 2F_c^2)/3$ 

### Table 1. Selected geometric parameters (Å, °)

N1C6	1.324 (4)	C8N9	1.371 (4)
N1-C2	1.345 (4)	N9-C10	1.436 (4)
C2—N3	1.313 (4)	C10-C11	1.490 (4)
C2-N21	1.402 (4)	C11-012	1.203 (3)
N3-C4	1.331 (3)	C11-013	1.319 (4)
C4N9	1.367 (4)	O13-C14	1.444 (5)
C4C5	1.379 (4)	N21—N22	1.219 (5)
C5—N7	1.379 (4)	N22—N23	1.127 (5)

C5—C6	1.400 (5)	N61—N62	1.250 (5)
C6—N61	1.389 (4)	N62—N63	1.121 (6)
N7—C8	1.304 (5)		
N3-C2-N1	128.4 (3)	N1-C6-N61	120.8 (3)
N3—C2—N21	114.1 (3)	N1-C6-C5	120.1 (3)
N1—C2—N21	117.5 (3)	N61-C6-C5	119.1 (3)
C4—N9—C10—C11	-76.8 (3)	N1-C2-N21-N22	-0.1 (4)
C8-N9-C10-C11	103.6 (3)	N1-C6-N61-N62	2.8 (5)

Structure determination by direct methods revealed all non-H atoms. Full-matrix least-squares refinement converged normally to reasonable geometry, including independent refinement of positions and isotropic displacement parameters for all H atoms. The azido groups show a monotonic increase in equivalent isotropic displacement parameters from the N atom attached to the free end indicating considerable atomic motion there.

Data collection: CAD-4 Software (Enraf-Nonius, 1989). Cell refinement: CAD-4 Software. Data reduction: DATREDXL (Brookhaven National Laboratory & University of Birmingham, 1986). Program(s) used to solve structure: MULTAN84 (Main, Germain & Woolfson, 1984). Program(s) used to refine structure: SHELXL93 (Sheldrick, 1993). Molecular graphics: ORTEPII (Johnson, 1976). Software used to prepare material for publication: SHELXL93.

The authors thank the EPSRC for a total technology studentship (GS), the EPSRC Mass Spectrometry Service (Swansea) and G. C. Clark (Aston University) for Mass Spectrometry analyses. We also thank Celltech Therapeutics (Slough) for continuous support of the DNA molecular recognition project and Drs M. A. W. Eaton and J. Turner for helpful discussions.

Lists of atomic coordinates, displacement parameters, structure factors and complete geometry have been deposited with the IUCr (Reference: BM1122). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

#### References

- Allen, D. W., Buckland, D. J. & Nowell, I. W. (1976). J. Chem. Soc. Perkin Trans. 2, pp. 1610–1612.
- Brookhaven National Laboratory & University of Birmingham (1986). DATREDXL. Program for Data Reduction. University of Birmingham, England.
- Chan, D. M. C., Sood, G., Schwalbe, C. H. & Fraser, W. (1995). Acta Cryst. C51, 2383–2386.
- Dueholm, K. L., Egholm, E., Behrens, C., Christensen, L., Hansen, H. F., Vulpius, T., Petersen, K. H., Berg, R. H., Nielsen, P. E. & Buchardt, O. (1994). J. Org. Chem. 59, 5767–5773.
- Egholm, M., Christensen, L., Dueholm, K. L., Buchardt, O., Coull, J. & Nielsen, P. E. (1995). *Nucleic Acids Res.* 23, 217–222.
- Enraf-Nonius (1989). CAD-4 Software. Version 5.0. Enraf-Nonius, Delft, The Netherlands.
- Hyrup, B. & Nielsen, P. E. (1996). Bioorg. Med. Chem. Lett. 4, 5–23. Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
- Kartsev, V. G., Aliev, Z. G., Voronina, G. N. & Atovmyan, L. O. (1990). Khim. Geterotsikl. Soedin. SSSR, pp. 515–519.
- Main, P., Germain, G. & Woolfson, M. M. (1984). MULTAN84. A Computer Program for the Automatic Solution of Crystal Structures from X-ray Diffraction Data. Universities of York, England, and Louvain, Belgium.

Sheldrick, G. M. (1993). SHELXL93. Program for the Refinement of Crystal Structures. University of Göttingen, Germany.

Thuong, N. T. & Hélène, C. (1993). Angew. Chem. Int. Ed. Engl. 32, 666-690.



Acta Cryst. (1997). C53, 610-612

# Structural Studies of Mitomycins. IX. 6-Demethyl-6-(phenylthiomethyl)mitomycin C

Nobutaka Sugaya, a Isao Fujii, Noriaki Hirayama, a<br/>\* Hitoshi Arai $^b$  and Masaji Kasai  $^b$ 

<sup>a</sup>Department of Biological Science and Technology, Tokai University, 317 Nishino, Numazu, Shizuoka 410-03, Japan, and <sup>b</sup>Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co. Ltd, 1188 Shimotogari, Nagaizumi, Sunto, Shizuoka 411, Japan. E-mail: hirayama@cbi.or.jp

(Received 8 July 1996; accepted 17 December 1996)

## Abstract

The title compound, (1aS)-6-amino-8-{[(aminocarbonyl)oxy]methyl}-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-(phenylthiomethyl)azirino[2',3':3,4]pyrrolo[1,2-*a*]indole-4,7-dione, C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>5</sub>S, is a C6-substituted methyl mitomycin C which possesses potent antitumor activities. The N4 atom is more pyramidal than the corresponding atom in both mitomycin C anhydride and mitomycin C dihydrate.

## Comment

Mitomycins are potent antitumor antibiotics produced by various Streptomyces cultures. Among these compounds, mitomycin C has been extensively used in cancer chemotherapy against a variety of solid tumors. Its use, however, is limited due to detrimental side effects. Many derivatives of mitomycins have been screened from nature and synthesized to obtain less toxic and more potent compounds. A series of C6-substituted methyl mitomycins was synthesized and evaluated for anticellular and antitumor activities (Arai et al., 1994). The results suggested that C6-substituted methyl mitomycins would have a different biological character from that of mitomycin C. We are undertaking the structural analysis of a series of C6-substituted methyl mitomycins in order to understand the structure-activity relationships and present here the structure of the title compound, (I).

An ORTEPII (Johnson, 1976) drawing of (I), together with the atomic numbering scheme is shown in Fig. 1. The absolute configuration of the molecule was suggested by referring to that of 1-N-(p-bromobenzoyl)mitomycin C (Shirahata & Hirayama, 1983). Most of the bond lengths are in the range observed in other mitomycins. The N1a-C1, N1a-C2 and C1-C2 bonds are significantly shorter than the corresponding bonds in both mitomycin C anhydride (MMCA) (Arora, 1979) and mitomycin C dihydrate (MMCD) (Ogawa, Nomura, Fujiwara & Tomita, 1979). The sum of the bond angles around N4 is 343.9 (6)°, significantly smaller than those around N4 in MMCA and MMCD, and N4 is more pyramidal than the corresponding atoms in MMCA and MMCD. The exocyclic bond angles around atoms C5. C6, C7 and C8 are highly asymmetric. The asymmetry around C6 is greatly increased in the title compound due to the large phenylthiomethyl substituent.



Fig. 1. ORTEPII (Johnson, 1976) drawing of the title compound showing the atomic numbering. Displacement ellipsoids are shown at the 30% probability level for non-H atoms and the H atoms are shown as small spheres of arbitrary size.